Scarica l'app Stockscreener
21.51
3.54%
-0.79
Dopo l'orario di chiusura:
21.51
Precedente Chiudi:
$22.30
Aprire:
$22.3
Volume 24 ore:
258.96K
Relative Volume:
1.57
Capitalizzazione di mercato:
$333.19M
Reddito:
$925.00K
Utile/perdita netta:
$-85.13M
Rapporto P/E:
-4.8581
EPS:
-4.4277
Flusso di cassa netto:
$-78.10M
1 W Prestazione:
-2.98%
1M Prestazione:
+23.76%
6M Prestazione:
+13.21%
1 anno Prestazione:
+28.04%
Intervallo 1D:
$19.86
$22.32
Intervallo di 1 settimana:
$19.86
$23.81
Portata 52W:
$6.875
$37.27
Neurogene Inc Stock (NGNE) Company Profile
Nome
Neurogene Inc
Settore
Industria
Telefono
(877) 237-5020
Indirizzo
535 W 24TH STREET, NEW YORK
Compare NGNE vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
21.51 | 333.19M | 925.00K | -85.13M | -78.10M | -4.4277 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-17 | Iniziato | Craig Hallum | Buy |
| 2025-05-16 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-06-27 | Iniziato | BMO Capital Markets | Outperform |
| 2024-06-11 | Iniziato | Robert W. Baird | Outperform |
| 2024-04-29 | Iniziato | Leerink Partners | Outperform |
| 2024-03-21 | Iniziato | William Blair | Outperform |
| 2024-01-08 | Iniziato | H.C. Wainwright | Buy |
| 2024-01-05 | Iniziato | Stifel | Buy |
| 2024-01-04 | Iniziato | TD Cowen | Outperform |
Mostra tutto
Neurogene Inc Borsa (NGNE) Ultime notizie
[144] Neurogene Inc. SEC Filing - Stock Titan
Neurogene to Participate in Stifel 2026 Virtual CNS Forum - Bluefield Daily Telegraph
Genetic-medicine firm Neurogene in Stifel 2026 virtual CNS fireside chat - Stock Titan
Neurogene Inc. (NASDAQ:NGNE) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
NGNE: Durable functional gains in Rett syndrome drive NGN-401's pivotal trial and commercial plans - TradingView
NGNE: NGN-401 shows durable, multi-domain gains in Rett syndrome, with pivotal data expected mid-2024 - TradingView
Gains Recap: Whats the analyst consensus on Neurogene Inc2026 Market Sentiment & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Will Neurogene Inc. stock outperform value stocksInsider Buying & Accurate Buy Signal Alerts - Naître et grandir
Aug Update: How correlated is Neurogene Inc to the S P500Chart Signals & Community Consensus Trade Alerts - baoquankhu1.vn
Layoff Watch: Is Neurogene Inc part of any major indexJuly 2025 PostEarnings & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Aug Movers: Is Neurogene Inc backed by strong institutional buyingJuly 2025 Breakouts & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Macro Review: Is Neurogene Inc in a long term uptrend2025 Market WrapUp & Weekly Market Pulse Updates - baoquankhu1.vn
Neurogene Inc. (NGNE) CFO sells 4,800 shares under 10b5-1 plan - Stock Titan
Neurogene announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - FinancialContent
NGNE SEC FilingsNeurogene 10-K, 10-Q, 8-K Forms - Stock Titan
Should You Buy Neurogene Inc (NGNE) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI
Neurogene: Stock Soars On FDA Designation For Rett Gene TherapyI'd Remain Cautious - Seeking Alpha
Canaccord Genuity Initiates Coverage of Neurogene (NGNE) with Buy Recommendation - Nasdaq
Neurogene (NASDAQ:NGNE) Now Covered by Canaccord Genuity Group - MarketBeat
This $20 Biotech Stock Just Got An FDA Boost – And A $200 Price Target - Stocktwits
FDA grants breakthrough therapy status to Neurogene’s Rett drug - Investing.com India
Why Is Neurogene Stock Skyrocketing Friday?Neurogene (NASDAQ:NGNE) - Benzinga
Neurogene : NGNE - 24/7 Wall St.
Neurogene Inc (ticker: NGNE) shares surged 32% in pre-market trading after the company announced that its experimental therapy for rare neurological diseases has received "Breakthrough Therapy" designation from the U.S. Food and Drug Administration (F - Bitget
Neurogene Gets FDA Breakthrough Tag For NGN-401 In Rett Syndrome; Stock Up - Nasdaq
FDA grants breakthrough therapy status to Neurogene’s Rett drug By Investing.com - Investing.com Australia
Neurogene Gains FDA Breakthrough Status for Rett Gene Therapy - TipRanks
Neurogene stock surges 30% on FDA breakthrough therapy status - Investing.com
Neurogene stock surges 30% on FDA breakthrough therapy status By Investing.com - Investing.com Australia
Neurogene Inc. wins FDA Breakthrough Therapy Designation for NGN-401 gene therapy - Traders Union
Neurogene Stock Soars On FDA Breakthrough Tag For Rett Gene Therapy - Bitget
Neurogene announces FDA breakthrough therapy designation for NGN-401 gene therapy for Rett syndrome - marketscreener.com
FDA grants Breakthrough status to Neurogene (NGNE) Rett gene therapy - Stock Titan
FDA fast-tracks one-time Rett syndrome gene therapy from Neurogene - Stock Titan
Neurogene Inc. (NGNE) Stock Analysis: Exploring a Potential 184.72% Upside in the Biotech Sector - DirectorsTalk Interviews
NGNE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Neurogene Inc. (NGNE) CSO awarded 16,500 restricted stock units - Stock Titan
Neurogene (NGNE) CMO receives new stock option and RSU grants - Stock Titan
[Form 4] Neurogene Inc. Insider Trading Activity - Stock Titan
Neurogene (NGNE) grants 12,050 non-qualified stock options to director Palekar - Stock Titan
Director at Neurogene (NGNE) granted 12,050 non-qualified stock options - Stock Titan
Neurogene Inc. (NGNE): Investor Outlook With A 232% Potential Upside - DirectorsTalk Interviews
Aug Analyst Calls: What is the earnings history of Neurogene IncJuly 2025 Action & Long-Term Investment Growth Plans - baoquankhu1.vn
Redmile discloses 9.9% Neurogene (NGNE) ownership stake via warrants and shares - Stock Titan
Is Neurogene Inc. stock near bottom after declineEarnings Overview Report & Safe Capital Growth Stock Tips - mfd.ru
Is Neurogene Inc. a potential multi baggerWeekly Profit Summary & Technical Buy Zone Confirmations - mfd.ru
How sensitive is Neurogene Inc. to inflationEntry Point & Reliable Price Breakout Alerts - mfd.ru
Can Neurogene Inc. outperform under higher oil pricesJuly 2025 Catalysts & Accurate Intraday Trade Tips - mfd.ru
How Neurogene Inc. stock reacts to oil prices2025 Key Highlights & Expert Approved Trade Ideas - mfd.ru
Neurogene Inc Azioni (NGNE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):